Related Experiment Videos
The relationship between depression and cardiovascular disorders
S Malhotra1, G E Tesar, K Franco
1Department of Psychiatry and Psychology, Cleveland Clinic Foundation, 9500 Euclid Avenue, Desk P57, Cleveland, OH 44022, USA.
Insights
Depression is a significant risk factor for cardiovascular disease, increasing the likelihood of cardiac events and mortality. The Sertraline Antidepressant Heart Attack Randomized Trial (SADHART) is a key study investigating antidepressant treatment for cardiovascular risk.
Area of Science:
- Cardiology
- Psychiatry
- Clinical Trials
Background:
- Growing evidence links cardiovascular disease (CVD) and depression.
- Depression independently elevates risks for cardiac events and mortality.
- Proposed mechanisms include HPA axis hyperactivity, autonomic dysfunction, and platelet reactivity.
Purpose of the Study:
- To investigate the impact of antidepressant therapy on cardiovascular risk.
- To evaluate the efficacy of sertraline in patients with cardiac conditions.
Main Methods:
- The Sertraline Antidepressant Heart Attack Randomized Trial (SADHART) was conducted.
- This trial represents a new series of studies on this topic.
Main Results:
- The SADHART trial has recently been completed.
- Results will inform future research on managing cardiovascular risk in depressed patients.
Conclusions:
- Antidepressant therapy may play a role in mitigating cardiovascular risk.
- Further studies are warranted to confirm the benefits of treating depression in cardiac patients.
Abstract:
Expanding scientific evidence supports a long-recognized link between cardiovascular disease and depression. As an independent risk factor, depression increases patient vulnerability to both cardiac events and mortality. Several important pathophysiologic mechanisms have been proposed, including hypothalamic-pituitary axis hyperactivity, autonomic nervous system dysfunction, and increased platelet reactivity, among others. The recently completed Sertraline Antidepressant Heart Attack Randomized Trial (SADHART) inaugurates a series of studies intended to address the impact of antidepressant therapy on cardiovascular risk.